Biologics in children's autoimmune disorders: Efficacy and safety

European Journal of Pediatrics

Volumn 170, Issue 2, 2011, Pages 157-167

  Breda, Luciana ^a   Del Torto, Marianna ^a   De Sanctis, Sara ^a   Chiarelli, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Biologic drugs; Efficacy; Juvenile idiopathic arthritis; Pediatric rheumatology; Safety

Indexed keywords

ABATACEPT; ADALIMUMAB; ARKALIST; CANAKINUMAB; CYTOKINE ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANAPHYLAXIS; ANCA ASSOCIATED VASCULITIS; ANKYLOSING SPONDYLITIS; ANXIETY; ANXIETY DISORDER; ASTHENIA; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; BONE NECROSIS; BRONCHOSPASM; CARDIOPULMONARY ARREST; CHICKENPOX; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CINCA SYNDROME; COUGHING; CROHN DISEASE; DEMYELINATING DISEASE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENCEPHALITIS; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HEART FAILURE; HEMATOMA; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; HYPERTENSION; HYPOTENSION; IMMUNOGENICITY; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INJECTION SITE BURNING; INJECTION SITE INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MUCKLE WELLS SYNDROME; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUSCLE SPASM; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; PRURITUS; PSORIATIC ARTHRITIS; RASH; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPONDYLOARTHROPATHY; T CELL LYMPHOMA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UVEITIS; VERTIGO; VISCERAL LEISHMANIASIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; AUTOIMMUNE DISEASES; BIOLOGICAL PRODUCTS; CHILD; HUMANS; TREATMENT OUTCOME;

EID: 78951491339     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-010-1238-z     Document Type: Review

References (97)

1. NE Aikawa JF De Carvalho CA Silva, et al. 2010 Immunogenicity of anti-TNFα agents in autoimmune diseases Clinic Rev Allerg Immunol 38 2-3 82 89 10.1007/s12016-009-8140-3
2. WP Arend JM Dayer 1990 Cytokines and cytokine receptors or antagonists in rheumatoid arthritis Arthritis Rheum 33 3 305 312 1:CAS:528:DyaK38XhvFaisrY%3D 10.1002/art.1780330302 2180403
3. T Arkachaisri TJ Lehman 2000 Use of biologics in the treatment of childhood rheumatic diseases Curr Rheumatol Rep 2 4 330 336 1:STN:280: DC%2BD38%2FgsF2mtQ%3D%3D 10.1007/s11926-000-0071-1 11123079
4. CM Bennett ZR Rogers DD Kinnamon, et al. 2006 Prospective phase I/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura Blood 107 7 2639 2642 1:CAS:528:DC%2BD28XjtlKltbk%3D 10.1182/blood-2005-08-3518 16352811
5. JA Bluestone EW St Clair LA Turka 2006 CTLA4Ig: bridging the basic immunology with clinical application Immunity 24 3 223 238 10.1016/j.immuni. 2006.03.001
6. RJ Brogan D Eleftheriou J Gnanapragasam, et al. 2009 Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report Pediatric Rheumatol 7 3 10.1186/1546-0096-7-3
7. A Calin BA Dijkmans P Emery, et al. 2004 Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis Ann Rheum Dis 63 12 1594 1600 1:CAS:528:DC%2BD2cXhtFaktbjM 10.1136/ard.2004.020875 15345498
8. L Castelo-Soccio AS Van Voorhees 2009 Long-term efficacy of biologics in dermatology Dermatol Ther 22 1 22 33 10.1111/j.1529-8019.2008.01213.x 19222514
9. LD Church S Savic MF McDermott 2008 Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap) Biologics 2 4 733 742 1:CAS:528:DC%2BD1MXjvVyhtb0%3D 19707454
10. SB Cohen P Emery MW Greenwald, et al. 2006 REFLEX Trial Group. Rituximab for rheumatoid arthritis to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 9 2793 2806 1:CAS:528:DC%2BD28XhtFWksLjI 10.1002/art.22025 16947627
11. S Cucchiara A Morley-Fletcher 2007 "New drugs: kids come first": children should be included in trials of new biological treatments Inflamm Bowel Dis 13 9 1165 1169 10.1002/ibd.20045 17455208
12. MI Danila LB Hughes SL Bridges 2008 Pharmacogenetics of etanercept in rheumatoid arthritis Pharmacogenomics 9 8 1011 1015 1:CAS:528: DC%2BD1cXpsFKqsL8%3D 10.2217/14622416.9.8.1011 18681777
13. JC Davis Jr D Van Der Heijde J Braun, et al. 2003 Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial Arthritis Rheum 48 11 3230 3236 1:CAS:528:DC%2BD3sXpvVygtb0%3D 10.1002/art.11325 14613288
14. F De Benedetti 2009 Targeting interleukin-6 in pediatric rheumatic diseases Curr Opin Rheumatol 21 5 533 537 10.1097/BOR.0b013e32832f1445 19593141
15. F De Benedetti A Martini 1998 Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 25 2 203 207 9489807
16. L de Ridder JC Escher J Bouquet, et al. 2004 Infliximab therapy in 30 patients, with refractory pediatric Crohn disease with and without fistulas in the Netherlands J Pediatr Gastroenterol Nutr 39 1 46 52 10.1097/00005176- 200407000-00010 15187780
17. AD Dick PG McMenamin H Korner, et al. 1996 Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinis despite quantitatively normal activated T cell traffic to the retina Eur J Immunol 26 5 1018 1035 1:CAS:528:DyaK28Xjt1Cru70%3D 10.1002/eji. 1830260510 8647162
18. WG Dixon K Watson M Lunt, et al. 2006 British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics register Arthritis Rheum 54 8 2368 2376 1:CAS:528:DC%2BD28XpsFGgu7g%3D 10.1002/art.21978 16868999
19. JC Edwards L Szczepanski J Szechinski, et al. 2004 Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 25 2572 2581 1:CAS:528:DC%2BD2cXkvFKntrc%3D 10.1056/NEJMoa032534 15201414
20. P Emery R Fleischmann A Filipowicz-Sosnowska, et al. 2006 DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: result of a phase IIB randomized, double-blind, placebo-controlled, dose ranging trial Arthritis Rheum 54 5 1390 1400 1:CAS:528:DC%2BD28XlsFSquro%3D 10.1002/art.21778 16649186
21. CS Foster F Tufail NK Waheed, et al. 2003 Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate Arch Ophthalmol 121 4 437 440 1:CAS:528:DC%2BD3sXjtlOht7Y%3D 10.1001/archopht.121.4.437 12695239
22. J Frenkel NM Wulffraat W Kuis 2004 Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins, et al. and Hoffman and Patel Arthritis Rheum 50 11 3738 3739 10.1002/art.20497 15529342
23. G Gartlehner RA Hansen BL Jonas, et al. 2008 Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence Clin Rheumatol 27 1 67 76 10.1007/s10067-007-0654-6 17570009
24. M Gattorno MA Pelagatti A Meini, et al. 2008 Persistent efficacy of anakinra in patients with tumor necrosis receptor-associated periodic syndrome Arthritis Rheum 58 5 1516 1520 1:CAS:528:DC%2BD1cXms1egs78%3D 10.1002/art.23475 18438813
25. M Gattorno A Piccini D Lasigliè, et al. 2008 The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis Arthritis Rheum 58 5 1505 1515 1:CAS:528:DC%2BD1cXms1egs74%3D 10.1002/art.23437 18438814
26. MC Genovese JC Becker M Schiff, et al. 2005 Abatacept for rheumatoid arthritis to tumor necrosis factor alpha inhibition N Engl J Med 353 11 1114 1123 1:CAS:528:DC%2BD2MXhtVWhsbnI 10.1056/NEJMoa050524 16162882
27. V Gerloni I Pontikaki M Gattinara, et al. 2005 Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor-α monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study Arthritis Rheum 52 3 548 553 1:CAS:528:DC%2BD2MXit1GjtLY%3D 10.1002/art.20793 15693004
28. R Goldbach-Mansky NJ Dailey SW Canna, et al. 2006 Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition N Engl J Med 355 6 581 592 1:CAS:528:DC%2BD28XotVKmt74%3D 10.1056/NEJMoa055137 16899778
29. B Granel J Serratrice P Disdier, et al. 2005 Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome Rheumatology (Oxford) 44 5 689 690 1:STN:280: DC%2BD2M3gs1ynsA%3D%3D 10.1093/rheumatology/keh547
30. KA Haines 2007 Juvenile idiopathic arthritis: therapies in the 21st century Bull NYU Hosp Jt Dis 65 3 205 211 17922671
31. PJ Hashkes RM Laxer 2005 Medical treatment of juvenile idiopathic arthritis JAMA 294 13 1671 1684 1:CAS:528:DC%2BD2MXhtVOqtLrI 10.1001/jama.294.13.1671 16204667
32. PJ Hashkes RM Laxer 2006 Update on the medical treatment of juvenile idiopathic arthritis Curr Rheumatol Rep 8 6 450 458 1:CAS:528:DC%2BD28XhtlWqt73M 10.1007/s11926-006-0041-3 17092444
33. K Hayward CA Wallance 2009 Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis Arthritis Res 11 1 216 227 10.1186/ar2619
34. HM Hoffman ML Throne NJ Amar, et al. 2008 Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies Arthritis Rheum 58 2443 2452 1:CAS:528:DC%2BD1cXhtVCjtbfL 10.1002/art.23687 18668535
35. G Horneff A Ebert S Fitter, et al. 2009 Safety and efficacy of once etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis Rheumatology (Oxford) 48 8 916 919 1:CAS:528:DC%2BD1MXptVagurY%3D 10.1093/rheumatology/kep122
36. NT Ilowite 2002 Current treatment of juvenile rheumatoid arthritis Pediatrics 109 1 109 115 10.1542/peds.109.1.109 11773549
37. NT Ilowite 2008 Update on biologics in juvenile idiopathic arthritis Curr Opin Rheumatol 20 5 613 618 10.1097/BOR.0b013e3283060778 18698187
38. N Ilowite O Porras A Reiff, et al. 2009 Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study Clin Rheumatol 28 2 129 137 10.1007/s10067-008-0995-9 18766426
39. JD Isaacs 2009 Antibody engineering to develop new antirheumatic therapies Arthritis Res Ther 11 3 225 10.1186/ar2594 19490600
40. PT Jones PH Dear J Foote, et al. 1986 Replacing the complementarity- determining regions in a human antibody with those from a mouse Nature 321 522 525 1:CAS:528:DyaL28Xkt1aksbY%3D 10.1038/321522a0 3713831
41. RB Jones AJ Ferraro AN Chaudhry, et al. 2009 A multicenter survey of rituximab therapy for refractory antinuetrophil cytoplasmatic antibody-associated vasculitis Arthritis Rheum 60 7 2156 2168 1:CAS:528:DC%2BD1MXptlKrsLo%3D 10.1002/art.24637 19565480
42. MM Katsicas RA Russo 2009 Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab Clin Rheumatol 28 8 985 988 10.1007/s10067-009-1162-7 19322622
43. M Khraishi 2009 Comparative overview of safety of the biologics in rheumatoid arthritis J Rheumatol Suppl 82 25 32 1:CAS:528:DC%2BD1MXotlSjur4%3D 10.3899/jrheum.090128 19509327
44. JM Kremer HK Genant LW Moreland, et al. 2006 Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial Ann Intern Med 144 12 865 876 1:CAS:528:DC%2BD28XntF2jsr8%3D 16785475
45. JB Kuemmerle-Deschner SM Benseler 2008 Abatacept in difficult to treat juvenile idiopathic arthritis Biologics 2 865 874 1:CAS:528:DC%2BD1MXjvVyhu74%3D 19707464
46. N Kutukculer S Caglayan F Aydogdu 1998 Study of pro-inflammatory (TNF-alpha, IL-1 alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters Clin Rheumatol 17 4 288 292 1:STN:280:DyaK1cvkslSjtw%3D%3D 10.1007/BF01451007 9776110
47. HJ Lachmann I Kone-Paut JB Kuemmerle-Deschner, et al. 2009 Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome N Engl J Med 360 23 2416 2425 1:CAS:528:DC%2BD1MXntVKqsrk%3D 10.1056/NEJMoa0810787 19494217
48. MJ Leandro JC Edwards G Cambridge 2002 Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion Ann Rheum Dis 61 10 883 888 1:CAS:528:DC%2BD38XotVSnsr8%3D 10.1136/ard.61.10.883 12228157
49. T Lequerré P Quartier D Rosellini, et al. 2008 Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France Ann Rheum Dis 67 3 302 308 10.1136/ard.2007.076034 17947302
50. DJ Lovell SL Bowyer AM Solinger 2005 Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease Arthritis Rheum 52 4 1283 1286 1:CAS:528: DC%2BD2MXktFCkur4%3D 10.1002/art.20953 15818707
51. DJ Lovell EH Giannini A Reiff, et al. 2000 Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group N Engl J Med 342 11 763 769 1:CAS:528: DC%2BD3cXit1Smu7k%3D 10.1056/NEJM200003163421103 10717011
52. DJ Lovell A Reiff NT Ilowite, et al. 2008 The Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis Arthritis Rheum 58 5 1496 1504 1:CAS:528:DC%2BD1cXms1egsrc%3D 10.1002/art.23427 18438876
53. DJ Lovell A Reiff OY Jones 2006 Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis Arthritis Rheum 54 6 1987 1994 10.1002/art.21885 16732547
54. DJ Lovell N Ruperto S Goodman, et al. 2008 Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis N Engl J Med 359 8 810 820 1:CAS:528:DC%2BD1cXhtVShur3O 10.1056/NEJMoa0706290 18716298
55. DJ Lovell N Ruperto L Jung 2006 Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results Arthritis Rheum 54 suppl s303
56. KL Madson TL Moore JM Lawrence, et al. 1994 Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis J Rheumatol 21 12 2359 2363 1:STN:280:DyaK2M3hsVSjtA%3D%3D 7699643
57. RN Maini PC Taylor J Szechinski 2006 CHARISMA Study Group. Double-blind randomized controlled clinical trial of interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate Arthritis Rheum 54 9 2817 2829 1:CAS:528:DC%2BD28XhtFWksLjK 10.1002/art.22033 16947782
58. A Martini A Ravelli LD Notarangelo, et al. 1986 Enhanced interleukin 1 and depressed interleukin 2 production in juvenile arthritis J Rheumatol 13 3 598 603 1:STN:280:DyaL283otFCmtQ%3D%3D 3090248
59. G Martini F Zulian 2006 Juvenile idiopathic arthritis: current and future treatment options Expert Opin Pharmacother 7 4 387 399 1:CAS:528: DC%2BD28XhvVKgurs%3D 10.1517/14656566.7.4.387 16503811
60. L Mastrandrea J Yu T Behrens, et al. 2009 Etanercept treatment in children with new-onset type 1 diabetes Diabetes Care 32 7 1244 1249 1:CAS:528:DC%2BD1MXps1KqsLc%3D 10.2337/dc09-0054 19366957
61. LJ McCann P Woo 2007 Biologic therapies in juvenile idiopathic arthritis: why and for whom? Acta Reumatol Port 32 1 15 26 1:STN:280: DC%2BD2s3kt12ntg%3D%3D 17450761
62. PJ Mease AJ Kivitz FX Burch, et al. 2004 Etanercept treatment of psoriatic arthritis : safety, efficacy, and effect on disease progression Arthritis Rheum 50 7 2264 2272 1:CAS:528:DC%2BD2cXmsVansbc%3D 10.1002/art.20335 15248226
63. T Mima N Nishimoto 2009 Clinical value of blocking IL-6 receptor Curr Opin Rheumatol 21 3 224 230 1:CAS:528:DC%2BD1MXkvVGrtrY%3D 10.1097/BOR. 0b013e3283295fec 19365268
64. B Neven I Marvillet C Terrada, et al. 2010 Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome Arthritis Rheum 62 1 258 267 1:CAS:528:DC%2BC3cXhtFGnurfL 10.1002/art.25057 20039428
65. M Nevyiel A Pontillo L Calligaris, et al. 2007 Diagnostics and therapeutic insights in a severe case of mevalonate kinase deficiency Pediatrics 119 2 523 527 10.1542/peds.2006-2015
66. N Nishimoto K Yoshizaki N Miyasaka, et al. 2004 Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial Arthritis Rheum 50 6 1761 1769 1:CAS:528:DC%2BD2cXlsFaqtL4%3D 10.1002/art.20303 15188351
67. SM O'Connell GM O'Regan T Bolger, et al. 2007 Response to IL-1 receptor antagonist in a child with familial cold autoinflammatory syndrome Pediatr Dermatol 24 1 85 89 10.1111/j.1525-1470.2007.00343.x 17300660
68. ML Olleros R Guler N Corazza, et al. 2002 Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-α J Immunol 168 7 3394 3401 1:CAS:528:DC%2BD38Xis1ajtrc%3D 11907097
69. Orencia product monograph (2006) Bristol Meyer Squibb Canada, Montreal. http://www.bmscanada.ca/upload/File/pdf/products/ORENCIA-E-PM- 17%20February%202010-APP-CLN.pdf
70. CE Pain LJ McCann 2009 Challenges in the management of juvenile idiopathic arthritis with etanercept Biologics 3 127 139 1:CAS:528: DC%2BD1MXmsFSmtL0%3D 19707402
71. V Pascual F Allantaz E Arce, et al. 2005 Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset arthritis and clinical response to IL-1 blockade J Exp Med 201 9 1479 1486 1:CAS:528:DC%2BD2MXktVCmurw%3D 10.1084/jem.20050473 15851489
72. P Quartier 2007 When should we use TNF antagonist in children with rheumatic disease? Join Bone Spine 74 1 3 1:CAS:528:DC%2BD2sXkt1Srtrw%3D 10.1016/j.jbspin.2006.07.001
73. A Rao M Kelly M Musselman, et al. 2008 Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias Pediatr Blood Cancer 50 4 822 825 10.1002/pbc.21264 17570702
74. A Reiff S Takei S Sadeghi, et al. 2001 Etanercept therapy in children with treatment-resistant uveitis Arthritis Rheum 44 6 1411 1415 1:CAS:528:DC%2BD38XpsFw%3D 10.1002/1529-0131(200106)44:6<1411::AID- ART235>3.0.CO;2-O 11407702
75. R Roldan AM Ruiz MD Miranda, et al. 2008 Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine Joint Bone Spine 75 504 505 10.1016/j.jbspin.2008.04.001 18541452
76. A Rubbert-Roth A Finckh 2009 Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review Arthritis Res Ther 11 suppl1 S1 10.1186/ar2666 19368701
77. N Ruperto DJ Lovell R Cuttica, et al. 2007 Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis Arthritis Rheum 56 9 3096 3106 1:CAS:528:DC%2BD2sXht1GgtbrM 10.1002/art.22838 17763439
78. N Ruperto DJ Lovell R Cuttica, et al. 2010 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension Ann Rheum Dis 69 718 722 1:CAS:528:DC%2BC3cXltlektrY%3D 10.1136/ard.2009.100354 20237125
79. N Ruperto DJ Lovell P Quartier, et al. 2008 Paediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial Lancet 372 9636 383 391 1:CAS:528:DC%2BD1cXpt1GqtLc%3D 10.1016/S0140-6736(08)60998-8 18632147
80. P Rutgeerts WJ Sandborn BG Feagan, et al. 2005 Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 23 2462 2476 1:CAS:528:DC%2BD2MXhtlShurjE 10.1056/NEJMoa050516 16339095
81. CM Samson N Waheed S Baltatzis, et al. 2001 Methotrexate therapy for chronic noninfectious uveitis Ophthalmology 108 6 370 374 10.1016/S0161-6420(01) 00576-0
82. H Schmeling G Horneff 2005 Etanercept and uveitis in patients with juvenile idiopathic arthritis Rheumatology (Oxford) 44 8 1008 1011 1:CAS:528:DC%2BD2MXmsV2is7o%3D 10.1093/rheumatology/keh658
83. R Sharma C Lal Sharma A Mahajan 2008 Biological agents targeting beyond TNF-alpha Indian J Crit Care Med 12 4 181 189 10.4103/0972-5229.45079 19742267
84. Y Shirota GG Illei NP Nikolov 2008 Biologic treatments for systemic rheumatic diseases Oral Dis 14 3 206 216 1:STN:280:DC%2BD1c3otF2qug%3D%3D 10.1111/j.1601-0825.2008.01440.x 18282173
85. JA Smith DJ Thompson SM Whitcup, et al. 2005 A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis Arthritis Rheum 53 1 18 23 1:CAS:528:DC%2BD2MXit1alsb0%3D 10.1002/art.20904 15696578
86. JS Smolen D Aletaha M Koeller, et al. 2007 New therapies for treatment of rheumatoid arthritis Lancet 370 9602 1861 1874 1:CAS:528:DC%2BD2sXhsVSgs7vF 10.1016/S0140-6736(07)60784-3 17570481
87. SR Targan SB Hanauer SJ van Deventer, et al. 1997 A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group N Engl J Med 337 15 1029 1035 1:CAS:528:DyaK2sXmvVKjsrs%3D 10.1056/NEJM199710093371502 9321530
88. SM Tse R Burgos-Vargas RM Laxer 2005 Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy Arthritis Rheum 52 7 2103 2108 1:CAS:528:DC%2BD2MXnsl2gtrY%3D 10.1002/art.21121 15986366
89. F Tubach D Salmon P Ravaud, et al. 2009 Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry Arthritis Rheum 60 7 1884 1894 1:CAS:528: DC%2BD1MXptlKktLo%3D 10.1002/art.24632 19565495
90. P Tynjälä K Kotaniemi P Lindahl, et al. 2008 Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis Rheumatology (Oxford) 47 3 339 344 10.1093/rheumatology/kem356
91. P Tynjälä P Lindahl V Honkanen, et al. 2007 Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis Ann Rheum Dis 66 4 548 550 10.1136/ard.2006.058248 17068061
92. JC van der Hilst EJ Bodar KS Barron, et al. 2008 International HIDS Study Group. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome Medicine (Baltimore) 87 6 301 310 10.1097/MD.0b013e318190cfb7
93. CA Wallace 2006 Current management of juvenile idiopathic arthritis Best Practice Res Clin Rheumatol 20 2 279 300 10.1016/j.berh.2005.11.008
94. D Wendling E Racadot J Wijdenes 1993 Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody J Rheumatol 20 2 259 262 1:STN:280:DyaK3s3jtlSktg%3D%3D 8474061
95. N Wilkinson G Jackson J Gardner-Medwin 2003 Biologics therapies for juvenile arthritis Arch Dis Child 88 3 186 191 1:STN:280: DC%2BD3s%2Fos1Gktg%3D%3D 10.1136/adc.88.3.186 12598373
96. S Yokota T Imagawa M Mori, et al. 2008 Efficacy and safety of tocilizumab in patients with systemic-onset idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial Lancet 371 9617 998 1006 1:CAS:528:DC%2BD1cXjs1Slur4%3D 10.1016/S0140-6736(08)60454-7 18358927
97. S Yokota T Miyamae T Imagawa, et al. 2005 Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis Arthritis Rheum 52 3 818 825 1:CAS:528:DC%2BD2MXjtVGjtLg%3D 10.1002/art.20944 15751095